CHINESE DRUG MAKERS
Drug factoryAnnual drug sales in China is estimated at $13.6 billion. Chinese drug companies market drugs through networks of wholesalers and pharmacies that exist in each province and major city. Many offer incentives to doctors to prescribe their drugs. Hospitals sell 80 percent of pharmaceuticals. Drug makers win contracts through competitive bidding.
Hisun Pharmaceutical is one of China’s largest drug makers. A small state-owned company that grew quickly into a large conglomerate, it exports a number of drugs approved by the United States Food and Drug Administration but also has produced toxic chemicals that have killed its workers and fouled the cities — Taizhou in Zhejiang — it is based. In one case workers died on two successive nights from breathing chemical-laden air after they were ordered to crawl inside and check a pipe used to dump waste into the sea.
China is a huge player in the medical supplies industry. It is the largest supplier of medicine ingredients in the world. More than 700 medical device companies in China make products — including stents and spinal screws — for the U.S.market,
Obtaining Drugs in China
About 40 percent of China’s healthcare spending is on drugs, a far higher share than in many countries. About a third of healthcare spending falls on individuals. In 2017, China announced plans to reduce the drug burden on patients and cover more vital drugs under national insurance. Patients taking drugs necessary for their survival — like the leukemia drug Gleevec — which began to be covered now only pay around 20 percent of the listed price. In 2018 China added a bunch of patented drugs from international drug companies to its national health insurance plan, securing massive price reductions in exchange for covering them. [Source: Echo Huang, Quartz, July 5, 2018]
Some Chinese have obtained generic versions of expensive drugs from India. Many drugs obtained there take some time to become available in China due to the lengthy approval process for foreign drugs.. Many Chinese people also travel to countries like Japan to buy basic, over-the-counter drugs, since drugs sold overseas are often perceived to be safer than those available in China. [Source: Echo Huang, Quartz, July 5, 2018]
The 2018 film “Dying to Survive” is based on the true story of a businessman who became a savior for hundreds of leukemia patients struggling to pay for expensive imported drugs. Debuting at the Shanghai Film Festival and the recipient of thousands of raves on Chinese film portal Douban, it tells the story of Cheng Yong, a peddler of viagra-like drugs who ends up helping a leukemia patient who can’t afford the drugs that keep her alive and cost over $6,000 a bottle. The patient asks Cheng to procure the generic version from India, which costs just a fraction of the price. After realizing the enormous profits to be made, Cheng assembles an unlikely team of smugglers — including a mother who strips to pay for her daughter’s leukemia treatments, and a priest. [Source: Echo Huang, Quartz, July 5, 2018]
According to Quartz: “Cheng’s character is based on the true story of Lu Yong, a textile trader who was diagnosed with leukemia, and spent more than $80,000 on Gleevec, a very effective treatment that wasn’t covered at the time under national health insurance. Manufactured by Swiss pharmaceutical firm Novartis, it cost the equivalent of $32 for a single pill. Lu located a generic substitute in India—and then helped get it to at least 1,000 other leukemia sufferers in China.
“The unapproved drug was considered counterfeit under Chinese law, and in 2014, Lu was arrested and charged with selling fake drugs. During his more than four months (link in Chinese) in detention, some 300 leukemia patients petitioned for his release. Lu was freed in 2015, with the prosecutor noting that he had never personally profited from the sales. After his story came to light, many drew parallels with Dallas Buyers Club—the 2013 film about a man who sells unregulated AIDS drugs to fellow HIV sufferers.
Western Drug Makers in China
China wants to attract world-class pharmaceutical laboratories. To get them to come the Chinese government is offering cheap clinical trials. Clinical trials are among the biggest costs for drug companies. Swiss-based Novartis, Britain’s GlaxoSmithKline and the U.S.’s Eli. Lilly are among the companies that have taken up the offer and invested of over $100 million in China.
Western drug companies that have entered the Chinese market include Pfizer, GlaxoSmithKline, Johnson & Johnson and Sanofi-Aventis. Among the drugs they sell in China are Johnson & Johnson’s Sudafed, Sanofi-Aventis’s sleeping pill Ambien and Pfizer’s cholesterol medicine Lipitor. The major American and European drug companies have spent over $1 billion in China over a 15 year period, hiring sales representatives and providing doctors with research grants and free trips. GlaxoSmithKline and others have plants in China.
Western drugs have had tough time breaking into the Chinese market even though they have medicines that could save and improve the lives of millions. One of the main obstacles is a preference for Chinese medicine and a prejudice for Western medicine. Even Chinese that drink Starbuck’s coffee and drive Buicks prefer herbs and acupuncture to foreign cold medicines and sleeping pills. The foreign companies also have to overcome government price controls, a ban on consumer advertising for prescription drugs and drugs by Chinese rivals that often win out in competitive bidding because they are cheaper.
In the 1990s, the New-Jersey-based mulinational drug company Merck helped the Chinese company Shenzhen Kangtai build drug-manufacturing facility in the city of Shenzhen and gave the company the biological technology to produce a hepatitis B vaccine royalty free, according to the New York Times, “ as part of an unusual joint venture aimed at improving health standards in China. At the time, up to two million Chinese children were being infected annually with hepatitis B. Since then, China has made great strides in early vaccinations under a national program subsidized by the government. And Shenzhen Kangtai became the country’s biggest producer of hepatitis B vaccines, with a 60 percent market share, according to China’s state-run news media. [Source: David Barboza, New York Times, December 25, 2013]
Foreign drugs companies including Britain's GlaxoSmithKline (GSK) have also been the target of wide-ranging probes. In 2013,GlaxoSmithKline was accused of channeling bribes to Chinese officials and doctors through travel agencies to boost sales illegally and raise the price of its medicines in the country. In 2014, the company was fined $490 million after a court found it guilty of bribery. According to to the BBC: The record penalty follows allegations the drug giant paid out bribes to doctors and hospitals in order to have their products promoted. The court gave GSK's former head of Chinese operations, Mark Reilly, a suspended three-year prison sentence and deported him. The company was accused of having made an estimated $150m in illegal profits. According to to Reuters: GSK sold $1.15 billion of pharmaceuticals and vaccines in China in 2012, up 17 percent on 2011, representing around 3.5 percent of the group total.[Source: BBC, September 19, 2014; Michael Martina, Reuters, July 15, 2013]
In 2004, the patent re-examination board of China's State Intellectual Property Office (SIPO) overturned Pfizer’s patent for erectile dysfunction drug Viagra.. “SIPO approved Pfizer's patent application for its anti-impotency drug Viagra in late 2001. But shortly after the patent was approved, twelve of the country's pharmaceutical companies launched a patent challenge, and were later joined by three more. In 2003, Pfizer sold 350,000 units of Viagra in China, where the drug is known as Wan Ai Ke/Wei Gee (“mighty brother”). The drug brought in global revenue of US$1.8 in 2003. [Source: Marius Meland, Law360, July 7, 2004]
Slow Approval of Foreign Vaccines in China
The Chinese vaccine market has grown grow at a rate of around 17 percent a year, reaching $3.7 billion in 2015 and was expected to reach $6 billion in 2018, according to McKinsey & Co. based on research reports. China requires drug companies to conduct local clinical trials on Chinese for products already approved elsewhere, sometimes with higher criteria for approvals than required by the WHO, leading to many years of delay before they become available. “"For multinationals there are hurdles to bring key products to market, including registration timelines," said Franck Le Deu, senior partner at McKinsey. [Source: Bloomberg News, April 13, 2016]
According to Bloomberg: “Vaccines made by Merck and Glaxo for HPV, or the human papillomavirus that can cause cervical cancer, are recommended by the World Health Organization for all countries. They are also not available in China and both companies have pending applications to sell them.
“At the heart of the problem is a massive pharmaceutical market where demand is outstripping the ability of regulators to keep up, forcing patients to scramble for many essential vaccines and hindering the ability of multinationals to bring them in. More than 30 vaccine products identified by top multinationals as major revenue generators in other parts of the world aren’t sold on the mainland, according to the consultancy.
“Merck submitted clinical trial data for its HPV vaccine Gardasil to the China Food and Drug Administration in 2012 and its application remains under review by the regulatory agency in 2016. First proved in 2006, Gardasil is now licensed in 130 countries, and was reported by the U.S. Centers for Disease Control and Prevention to reduce prevalence of the types of HPV it covers in teenage girls by 64 percent, Merck said. China is estimated to have close to 100,000 new cervical-cancer cases in 2015, according to a recent study based on the National Central Cancer Registry of China published in a journal.
Chinese Go to Hong Kong to Get Vaccines
The stiff regulations that prevent China’s 1.4 billion people from accessing several common vaccines available in much of the rest of the world have forces some parents to go to Hong Kong or other countries to get them. Bloomberg reported: Sam Ding, a tech professional in southern China, says he crossed the border to Hong Kong twice to get his one-year-old daughter a key vaccine for potentially fatal conditions — pneumonia, blood infections and meningitis. [Source: Bloomberg News, April 13, 2016]
“Ding said he was willing to travel to Hong Kong twice because he felt it was very important that his daughter get the pneumococcal vaccine. "After she was born I was more worried about pneumonia," he said. "China’s environmental hygiene isn’t very good and it’s so densely populated, pneumonia is a serious matter."
“The pneumococcal vaccine has gradually disappeared from mainland China after Pfizer’s license to sell the shot expired a year ago. Chinese regulators are yet to approve Pfizer’s latest version of the vaccine, called Prevenar 13, which sells all over the world. China has no other approved pneumococcal vaccines for children under two, although the shot is among those recommended by the World Health Organization for all countries.
Chinese-Made Vaccines on the Rise
Gillian Wong of Associated Press wrote: “China's vaccine makers are gearing up over the next few years to push exports in a move that should lower costs of lifesaving immunizations for the world's poor and provide major new competition for the big Western pharmaceutical companies. However, it may take some time before some parts of the world are ready to embrace Chinese products when safety is as sensitive an issue as it is with vaccines — especially given the food, drug and other scandals the country has seen. Still, China's entry into this market will be a "game changer," said Nina Schwalbe, head of policy at the GAVI Alliance, which buys vaccines for 50 million children a year worldwide. "We are really enthusiastic about the potential entry of Chinese vaccine manufacturers," she said. [Source: Gillian Wong, Associated Press, November 29, 2011]
China's vaccine-making prowess captured world attention in 2009 when one of its companies developed the first effective vaccine against swine flu — in just 87 days — as the new virus swept the globe. In the past, new vaccine developments had usually been won by the U.S. and Europe. Then, in March 2011 the World Health Organization announced that China's drug safety authority meets international standards for vaccine regulation. It opened the doors for Chinese vaccines to be submitted for WHO approval so they can be bought by U.N. agencies and the GAVI Alliance.
"China is a vaccine-producing power" with more than 30 companies that have an annual production capacity of nearly 1 billion doses — the largest in the world, the country's State Food and Drug Administration told The Associated Press. But more needs to be done to build confidence in Chinese vaccines overseas, said Helen Yang of Sinovac, the NASDAQ-listed Chinese biotech firm that rapidly developed the H1N1 swine flu vaccine. "We think the main obstacle is that we have the name of 'made in China' still. That is an issue."
First up is likely to be a homegrown vaccine for Japanese encephalitis, a mosquito-borne disease that can cause seizures, paralysis and death. The vaccine has been used for two decades in China with fewer side effects than other versions. Its manufacturer expects WHO approval for it in about a year. Also in the works are vaccines for polio and diseases that are the top two killers of children — pneumonia and rotavirus, which causes diarrhea.
Plasma making machines
Concerns About Chinese-Made Vaccines
Gillian Wong of Associated Press wrote: “China's food and drug safety record in recent years hardly inspires confidence: in 2007, Chinese cough syrup killed 93 people in Central America; one year later, contaminated blood thinner led to dozens of deaths in the United States while tainted milk powder poisoned hundreds of thousands of Chinese babies and killed six. The government has since imposed more regulations, stricter inspections and heavier punishments for violators. Perhaps because of that, regulators routinely crack down on counterfeit and substandard drugmaking. [Source: Gillian Wong, Associated Press, November 29, 2011]
While welcoming WHO's approval of China's drug safety authority, one expert said it takes more than a regulatory agency to keep drugmakers from cutting corners or producing fakes. "In the U.S., we have supporting institutions such as the market economy, democracy, media monitoring, civil society, as well as a well-developed business ethics code, but these are all still pretty much absent in China," said Yanzhong Huang, a China health expert at the Council on Foreign Relations. "For China, the challenge is much greater in building a strong, robust regulative capacity."
In 2010, a Chinese newspaper report linked improperly stored vaccines to four children's deaths in northern Shanxi province, raising nationwide concern. The Health Ministry said the vaccines did not cause the deaths, but some remained skeptical. Meanwhile, Chinese researchers reported in the New England Journal of Medicine earlier this year that a pandemic flu vaccine given to 90 million people in 2009 was safe. WHO's medical officer for immunization, Dr. Yvan Hutin, said WHO's approval of the Chinese drug regulatory agency is not "a blank check." Each vaccine will be evaluated rigorously, with WHO and Chinese inspectors given access to vaccine plants on top of other safety checks, he said. For China, the 2010s has been crucial, as biotech companies upgraded their facilities and improved procedures to meet the safety and quality standards — a process that has been costly and challenging. Then have submitted vaccines to the U.N. health agency for approval.
Hopes That Chinese-Made Vaccines Will Bring the Costs of Vaccines Down
Gillian Wong of Associated Press wrote: “Vaccines also are a significant part of a $300 million partnership with the Bill & Melinda Gates Foundation for the development of new health and farming products for poor countries. China's entry into this field is important because one child dies every 20 seconds from vaccine-preventable diseases each year. UNICEF, the children's agency and the world's biggest buyer of vaccines, has been in talks with Chinese companies, said its supply director Shanelle Hall. The fund provides vaccines to nearly 60 percent of the world's children, and last year spent about $757 million. [Source: Gillian Wong, Associated Press, November 29, 2011]
Worldwide, vaccine sales in 2010 grew 14 percent to $25.3 billion, according to healthcare market research firm Kalorama Information, as drugmakers which face intensifying competition from generic drugs now see vaccines as key areas of growth, particularly in Latin America, China and India. China's vaccine makers, some of whom already export in small amounts, are confident they will soon become big players in the field. "I personally predict that in the next five to 10 years, China will become a very important vaccine manufacture base in the world," said Wu Yonglin, vice president of the state-owned China National Biotec Group, the country's largest biological products maker that has been producing China's encephalitis vaccine since 1989.
CNBG invested more than $1.5 billion between 2011 nd 2015 to improve its facilities and systems to meet WHO requirements. The company submitted vaccines to fight rotavirus, which kills half a million kids annually, and polio for WHO approval. Smaller, private companies are also positioning themselves for the global market. Sinovac is now testing a new vaccine for enterovirus 71, which causes severe hand, foot and mouth disease among children in China and other Asian countries. It is also preparing for clinical trials on a pneumococcal vaccine Yang says could rival Pfizer's Prevnar, which was the top-selling vaccine worldwide last year with sales of about $3.7 billion. Pneumococcal disease causes meningitis, pneumonia and ear infection. "In the short term, everyone sees the exporting opportunities, because outside of China the entire vaccine market still seems to be monopolized by a few Big Pharma (companies)," Yang said.
The entry of Chinese companies is expected to further pressure Western pharmaceutical companies to lower prices. In 2011, UNICEF's move to publicize what drugmakers charge it for vaccines showed that Western drugmakers often charged the agency double what companies in India and Indonesia do. The aid group Doctors Without Borders criticized the vaccine body GAVI for spending hundreds of millions of dollars on anti-pneumonia vaccines from Western companies, saying it could put its buying power to even better use by fostering competition from emerging manufacturers like those in China. GAVI's Schwalbe said the vaccine body has to buy what is available and negotiates hard for steep discounts. "We need to buy vaccines now to save children's lives now. We can't wait."
Vaccine Scandals in China
In 2018, there was a big uproar on the Chinese internet over news that Changchun Changsheng, a vaccine producer in China’s northeastern Jilin Province, forged data and produced over 250,000 substandard vaccines. Sup China reported: “The good news: The chairwoman of Changchun Changsheng has been detained, the company has been fined over half a million dollars and is under investigation, and the substandard vaccines have been recalled. Alipay launched a feature to help parents track vaccinations their children receive. Also, fortunately, no reports have emerged of this particular batch of vaccines causing harm or death, but that was not the case in multiple previous vaccine and food safety scandals. [Source: SupChina, July 24, 2018]
There have also been reports of children dying or becoming seriously ill from faulty encephalitis, hepatitis B and rabies vaccines. “The entire vaccination safety system in China is in crisis, the South China Morning Post reported, as it has been “tainted by corruption, weak regulations and staff shortages.” One former employee of the National Institutes for Food and Drug Control told the South China Morning Post that the punishment received for selling substandard vaccines is actually miniscule, describing it as “only one hair on nine oxen to the pharmaceutical companies, and far from intimidating to them.”
In 2013, Health authorities in China investigated one of China’s biggest vaccine makers after 17 people, including eight infants, died in past two months following injections of hepatitis B vaccine. The New York Times reported: The government said that it had suspended the use of millions of doses of a hepatitis B vaccine produced by the manufacturer, Shenzhen Kangtai Biological Products. Government. Six of the deaths have been linked to vaccines produced by Shenzhen Kangtai; the two other infant deaths occurred recently after the use of a hepatitis B vaccine produced by another drug maker, Beijing Tiantan Biological Products. Investigators have not determined the cause of the deaths or linked them directly to the injections, but the cases come at a time of growing public concern in China about food and drug safety problems. [Source: David Barboza, New York Times, December 25, 2013]
A few weeks later, Chinese health authorities said they have found no link between a hepatitis B vaccine and the deaths of nine children who had received those shots. Reuters reported: China has been investigating 17 deaths following inoculation with a hepatitis B vaccine, made by Shenzhen-based BioKangtai, from December 13 and 31. The news alarmed many Chinese Internet users, who called on the government to make more information public. “Nine of the cases have nothing to do with the vaccines, state news agency Xinhua cited the director of the disease control bureau of the National Health and Family Planning Commission, Yu Jingjin, as saying at a press conference.A preliminary analysis of the eight other cases have also found no link between the deaths and the vaccines, but the cause of the deaths will be confirmed only after autopsies, Yu said. [Source: Reuters, January 3, 2014]
According to Bloomberg: “Public faith in China’s vaccine system suffered another blow in 2016 after police in Shandong province in eastern China arrested a mother-daughter team for allegedly selling more than $88 million worth of vaccines illegally in 18 provinces since 2011. Local police said the pair distributed products that may have been improperly stored and transported, the official Xinhua news agency reported. [Source: Bloomberg News, April 13, 2016]
Drug Safety in China
In Panama 174 people were poisoned, 115 of them fatally, with others disabled, after taking a Chinese-made cough medicine contaminated with diethylene glycol (DEG), a poisonous chemical often found in solvents and antifreeze. The deaths were blamed on mislabeling — the cough medicine labels said the medicine contained glycerin, a safe sweetener, not DEG. After the news was revealed further digging revealed the presence of DEG in toothpaste sold around the globe (See Unsafe Toothpaste, Food) and that fake glycerin produced by a state-owned company in China killed nearly 100 children in Haiti.
In September 2007, methotrexate and cytarabin — two medicines used to treat leukemia and rheumatoid arthritis — were recalled after being linked to adverse reactions in several young leukemia patients in Guangxi autonomous region in southern China. Some patients complained of pain. Others had difficulty walking after being injected with the drug.
The five main agencies in charge of food and drug safety fight among themselves and suffer from a lack of personal and equipment. Whistle blowers, even individuals who post whistleblower messages on the Internet, end up in jail.
There are plenty of adequate laws and regulations. The problem is enforcement. Yasgenh Huang, a professor at MIT’s Sloan Business School told the New York Times, “The issue is not whether Chinese businesses are regulated: they are. The issue is that the regulators are unable to be impartial in the enforcement of the laws. Those laws are meaningless in a system that does not even pretend to have judicial independence, media freedom and legislative oversight.”
See Food Safety
Heparin Scare in China
In 2007 and 2008, hundreds of patients had reactions including — including breathing difficulty, vomiting, rapidly falling blood pressure and in some cases life-threatening shock — after taking heparin, a blood-thinning drug made by Baxter International from the linings of pig intestine, At least 19 died, The reactions were linked to the substitution of a fake ingredient for an active ingredient at a factory in China. Investigators were trying to determine whether the substitution was accidental or deliberate
The substance used the Baxter heparin — an inexpensive, unapproved chemical called chondroitin sulfate, used to treat joint pain, altered to mimic the real active ingredient in heparin — was made by a Chinese company called Changzhou SP, which in turn bought its heparin from companies that gather crude heparin form pig intestines.
Evidence seems to indicate intentional counterfeiting. The active ingredient in heparin and the substitute can be uncovered with special tests using magnetic resonance equipment. Such tests determined that up to 50 percent of the active ingredient in the heparin was a mimic heparin. The substitute seems to have been added as a cheap filler. Some have speculated that the fake ingredient may have been substituted because an outbreak of pig disease had dried up the supply of pig intestine Chondroiton sulfate, which can be obtained from pig cartilage and costs about out one twentieth the price of heparin to produce.
An official at Baxter said that it appeared the heparin produced in China had been deliberately contaminated. The industry which revolves around pig farmers that supply the intestines and processors that make crude heparin are not regulated and have little oversight. Most facilities have never been inspected.
China Detains Dozens in Poison Drug Capsule Scandal
In April 2012, Reuters reported: “Chinese police have detained 45 people, arrested nine and seized more than 77 million capsules tainted with chromium in China's latest product safety scandal, which has aroused widespread public concern despite repeated pledges to get tough. The government said the companies involved sold gel capsules made with industrial gelatin, which contains a far higher chromium content than the edible gelatin they should have used. While there have been no reports of deaths or sickness caused by taking the contaminated capsules, long-term exposure to chromium can cause serious organ damage and cancer. [Source: Reuters, Ben Blanchard April 22, 2012]
“In a statement issued late, the Ministry of Public Security said they had also shut down 80 illegal production lines after a week of inspections centered on Zhejiang, Hebei and Jiangxi provinces. "The ministry is paying top level attention to the case of excess chromium in capsules of medical use, and is dispatching investigation teams on a daily basis," it said in the statement carried on its website. The ministry "is pushing with all its strength for speedy investigations and speedy resolutions", the statement said.
“While the government has repeatedly vowed to crack down, tackling the issue has not been helped by China's confused and still developing regulatory environment. They gel capsules “are treated as neither food nor drugs. Related authorities have limited knowledge about how capsules would affect people's health," Wang Chengdong at the China University of Political Science and Law told the official China Daily.
A few days earlier AFP reported: “Chinese police have detained 22 people for making drug capsules using a toxic raw material produced from scrap leather, state media said. Police in the eastern province of Zhejiang found the suspects allegedly made and sold capsules with excessive levels of chromium after using industrial gelatin made from discarded leather, the Xinhua News agency said. Chromium has several industrial uses including leather tanning. AFP, April 16, 2012]
According to Xinhua, at least half of the people detained worked for capsule makers in Zhejiang's Xinchang county, a major production base. According to the report, the industrial gelatin used to make the capsules came from other factories in the northern province of Hebei and the eastern province of Jiangxi. In another twist to the scandal, police also detained a factory owner in Hebei for allegedly setting fire to his own plant to destroy evidence of making industrial gelatin, Xinhua said in a separate report.
“Song Xunjie, manager of the Xueyang Glair Gelatin Factory, is said to be a supplier to companies across the country, it added. The government's State Food and Drug Administration (SFDA), the industry regulator, also suspended sales of 13 types of drugs confirmed to have excessive levels of chromium.
Unsafe Toothpaste in China
People who used Springfresh toothpaste, imported from China found it was good at whitening teeth and also effective cleaning shoes and removing stains. Later it was found the toothpaste contained diethylene glycol (DEG), a poisonous chemical often found in solvents and antifreeze
Tainted toothpaste imported from China has turned up in the United States, Panama, the Dominican Republic and Australia. The FDA in United States, after being alerted by officials in Panama, issued a warning on more than a dizen brands of toothpaste manufactured in China, including Mr. Cool. Everfresh Smile-2, Superdent and Springfresh, some of which sold for as little as nine cents a tube wholesale. Some tubes of Springfresh contained 6 percent DEG.
Manufacturers had substituted DEG for a more expensive sweeteners such glycerin which is used in U.S.-made toothpaste as a sweetener and a bonding agent. Chinese customs found the DEG in the toothpaste but did not regard it as dangerous and let it pass. DEG was banned in the United States in 1937 after 105 people died taking a medicine in which it was one of the ingredients. Even so it is not banned in China.
Springfresh toothpaste is manufactured a plant in Suzhou, a tourist town near Shanghai. DEG is not necessarily life threatening. No one in the United States reported becoming ill from it. An adult would have to consume 275 tubes of it to receive a toxic dose. The Chinese government has no regulations banning the chemicals in toothpaste. It responded to the problem by drawing up a new set of “strict certification and evaluation procedures” to “improve the safety and hygiene of oral health care products.”
Problems with China’s Drug Industry
There are over major 5,000 drug makers and of thousands more small, unregulated drug and drug ingredient producers. Some companies routinely substitute fake or substandard ingredients. Others bribe officials and submit false information to get their drugs approved. Zheng Xiaoyu, former head of the SFDA, was executed in 2007 for accepting $850,000 in bribes in exchange for granting approval for hundreds of medicines, some later found to be dangerous (See Below).
The Chinese drug industry is poorly regulated. It is hard to keep a watch on all of the drug makers and producers. Safety regulators are governed by bosses who often respond more to their own agenda than to rules and regulations they are supposed to enforce and are susceptible to bribes from the people they are supposed to watch over.
One of the problem is there is virtually no regulation in the drug ingredient industry, where many of the problems originate. Some of the ingredient makers export steroids and human growth hormone used in illegal performance-enhancing drugs used by athletes. Others make counterfeit ingredients that are put unknowingly into drugs. Unlike drug companies they are not regulated by the food and drug and agency. They also are not regulated by other agencies that keep watch on chemical companies that produce things like solvents and fertilizers.
Many drug ingredients are produced by chemical companies that are neither certified or inspected. These companies make ingredients that are used by Chinese drug makers and are exported to foreign drug makers. Because there are few laws and regulations in their sector there is little to stop from exporting unapproved doctored or counterfeit ingredients. In some cases they have passed off poison as legitimate ingredients (See Pet Food and Toothpaste, Food).
Among the Chinese chemical makers investigated by the New York Times that produced questionable drugs are Honor International, which shipped counterfeit Viagra labeled as “grape seed extract” to the United States; Orient Pacific International, whose owner was arrested in Houston for selling counterfeit dugs for prostrate cancer, Alzheimer’s disease and schizophrenia; GeneSciense Pharmaceutical, indicted on charges of smuggling and illegally selling human growth hormone; and CNSC, the source of ingredient that killed or disabled 139 Panamanians. All of these companies were present at an exhibition for drug ingredient makers in Milan in 2007.
Response to Poor Drug Safety in China
A government watchdog agency revoked the production licenses of five drug manufacturers in 2006 and 2007 and withdrew good manufacturing practice certificates from 128 others. Among the companies that were shut down were Qiqihar No.2 Pharmaceutical Co, following the deaths of 11 people who took a drug it manufactured. The company said that it traced the poisonous ingredient to a chemical supplier that substituted a less-expensive but dangerous agent for an inactive ingredient in the drug.
Taixing Glyercin Fatcory, the source of much of the DEG, was also shut down. It was charged with fraudulently passing off DEG as glycerin. Xuzhou Anying Biologic technology and Binzhou Futian Biology Technology, the sources of melamine found in some of the pet food, had their licenses revoked.
In July, 2007, China’s top food and health official, Zheng Xiaoyu, was executed on corruption charges in connection with taking $850,000 in bribes from eight companies in return for approving untested drugs. He was executed within a few weeks of when a court handed down his death sentence. The swift move was largely seen as both an effort to reassure the international community that China was serious about tackling safety issues and an example of “slaughtering the chicken to warn the monkey” to keep other officials in line. It was the first time an official of such a high tank had been executed since 2000. Zheng’s execution was popular among ordinary Chinese.
Zheng clearly helped drugs companies that paid him off. One of them, Kangliyuan posted sales of $206 million in 2006, up from $26 million in 2002, despite the fact that many of the drugs it produced substituted neutral ingredients for real medicines and repackaged generic drugs as their own. Kangliyuan gave Zheng a lakeside house and thousands of dollars in bribes. More than 170,000 drugs that received authorization under Zheng’s tenure from 1998 to 2005 are now under review
In July 2007, one of Zheng’s assistants Gao Zicheng was sentenced to death with a two year reprieve, a sentence which usually is commuted to life in prison, for accepting bribes totaling $307,000 from two drug companies. He oversaw a pharmaceutical registration agency accused of approving substandard medicines, including an antibiotics blamed for at least 10 deatha.
Fake Medicine in China
Fake medicine is a serious problem in China. In some Chinese cities as much as 40 percent of all the drugs sold are counterfeit. They include antibiotic made with talcum power and birth control pills filled with rice flour. Six different version of knock-off Viagra are available in some airport drugstores. China is believed to be the source of many of the fake medicines sold around the globe. Counterfeit drugs made in China have turned up in almost every country. Many of the fake drugs sold over the Internet are produced in China or are made with ingredients produced in China.
By one estimate 200,000 people die each year in China from taking fake drugs. Some are unauthorized copies. Others are made with substandard ingredients. Yet others are made with ingredients that do nothing or are even harmful to users. Many people are involved in the trade. The sentences for getting caught are relatively light.
Some counterfeit drugs are made by illegal labs. Others are made legal labs and legitimate drug companies. Yet others are made by legal labs and legitimate drug companies using counterfeit ingredients. It is often not clear whether these labs and companies knowingly or unknowingly use the counterfeit ingredients.
In 2001, 1,300 drug-counterfeiting factories were shut down and 480,000 cases of fake drugs was investigated. Many of the factories reopened somewhere else. Owners are often tipped off about investigations by police who are bribed by them. Much of the work in locating the factories being done to by private investigators hired by the drug companies.
In May 2006, 13 people died in Guangzhou after being injected with a fake medicine. A few months later 10 more people died in similar fashion in Anhui Province. In May 2008 a factory producing fake medicine was found inside a hospital in Beijing. Patients were given fake medicines that was said to cure everything from hepatitis to mental illness. Patients paid around $1,000 for treatment with the drugs which hospital officials said would cure them.
In Japan in 2001 and 2002, hundred of people became sick and four people died from liver problems after taking Chinese-made diet pills purchased over the Internet. The pills escaped regulators scrutiny by being classified as a diet aid rather a drug. One woman told Reuters that after she took the controversial diet pills said she quickly lost weight after taking them, b ut not long afterwards she started to feel lethargic and nauseous. She was convinced that she might have died if she had been warned that they were dangerous.
The government also announced cracked down on criminal rings that ran huge manufacturing centers that produced everything from fake Viagra to counterfeit Tamiflu, and anti-malaria drugs to imitation Crest toothpaste. In November 2011, authorities busted a gang that produced and sold fake medicine — some made of animal feed — arresting 114 suspects and seizing more than 65 million counterfeit tablets.
2,000 Arrested in China in Counterfeit Drug Crackdown
In August 2012, Chinese government authorities detained nearly 2,000 people as part of a nationwide crackdown on the sale of fake or counterfeit drugs and health care products, according to a report on Sunday from Xinhua, the official news agency. The New York Times reported: “The government said that it had mobilized more than 18,000 officers in recent weeks to break up drug counterfeiting rings and that officials had seized about $182 million in fake medicine, including fraudulent drugs for the treatment of cancer, hypertension and diabetes. [Source: David Barboza, New York Times August 5, 2012]
“The crackdown comes amid growing concerns about the prevalence of counterfeit drugs and tainted food supplies in China, and increasingly sophisticated counterfeiting operations. The government acknowledged that the manufacturing of fake drugs had become harder to detect. Earlier this year, the authorities in Zhejiang Province, not far from Shanghai, discovered that hospital workers were saving old packages, including those of high-end medications, and reselling them to drug counterfeiters to refill with fake drugs.
“In May 2012, the authorities announced the arrest of 200 people accused of making and selling fake drugs. The government has said many of the fake medicines were being marketed on Internet sites, giving counterfeiters a way to sell directly to consumers. Although the government has repeatedly vowed to step up food and drug safety measures and announced the arrests of counterfeiters and the closing of scores of underground operations, the scandals seem to resurface every few months. In 2007, the government even executed the former director of the food and drug watchdog agency for failing to properly supervise the marketplace. The recent crackdown comes because of concern that some of the fake treatments are leading to liver damage and even cardiac arrest. In a statement released Sunday, the Ministry of Public Security said that it would offer rewards of about $8,000 to those who help uncover fake medicine operations.
Unusual Treatments and Medicines in China
People drink heated apple vinegar to clean the stomach. In the 1960s, million of people went to hospitals to get injections of chicken blood extract in hopes that it would extend their lives.
People with spinal chord injuries are sometimes treated with the mucous cells from aborted fetuses. In the treatments patients are injected with cultured cells — collected from the noses of the fetuses — into an area around the injured areas of patients with spinal chord lesions. Although the legality and effectiveness of such transplants have not been worked out doctors who do the treatments claim they helps regenerate nerve cells of the spinal chord and help patients regain some feeling and movement. The procedure is carried out by a doctor at the Medical Science Hospital in Beijing. Many foreigners with spinal injuries travel to Beijing for the treatments.
Urine is used to extract steroids, pituitary hormones and sublimated hormone crystals used in endocrinology. The Chinese have been using human urine for medicine for thousands of years. In ancient China it was used it to treat a number of conditions, including impotence, hypogonadism and dysmenorrhea. More recently hormones taken from urine has been used to straighten out hermaphrodites. [Source: Paul Theroux]
Urine is collected for medicinal uses and fertilizer in 65-gallon drums. . Theroux saw a sign over a urinal at a public restroom that read "We would like good quality urine, so please do not put anything in — no spitting, no paper, no cigarette butts."
Caterpillar fungus, See Tibet
Drugs Made from Dead Babies in Northeast China
In May 2012, The Guardian reported: “South Korea has seized thousands of smuggled drug capsules filled with powdered flesh from dead babies, which some people believe can cure disease. The capsules were made in northeast China from babies whose bodies were chopped into small pieces and dried on stoves before being turned into powder, the Korean customs service said. [Source: The Guardian, May 7, 2012]
The customs service said it had discovered 35 attempts since August to smuggle a total of about 17,450 capsules. The smugglers told customs officials they believed the capsules were ordinary stamina boosters, and were ignorant of the ingredients and manufacturing process. Ethnic Koreans from northeast China who now live in South Korea intended to use the capsules themselves or share them with other Korean-Chinese, a customs official said.
“The capsules were carried in luggage or sent by international mail. They were all confiscated but no one was punished because the amount was deemed small and they were not intended for sale, the official said. The customs agency began investigating after receiving a tip a year ago. No sicknesses have been reported from ingesting the capsules. Officials refused to say where the dead babies had come from or who made the capsules, citing possible diplomatic friction with Beijing. Last year, Chinese officials ordered an investigation into the production of drugs made from dead foetuses or newborns.
Image Sources: Wikicommons, Nolls China website http://www.paulnoll.com/China/index.html
Text Sources: New York Times, Washington Post, Los Angeles Times, Times of London, National Geographic, The New Yorker, Time, Newsweek, Reuters, AP, Lonely Planet Guides, Compton’s Encyclopedia and various books and other publications.
Last updated August 2022